98%
921
2 minutes
20
GENTA nephrotoxicity is likely to be caused, among other factors, by an increase of vasoconstrictors or a decrease of vasodilators such as NO. Few days after discontinuing GENTA treatment, the renal function is recovered, but if risk factors like advanced age, previous renal dysfunction, simultaneous use of other nephrotoxic drugs or dehydration are present, severe and progressive renal disease occurs. The aim of this study was to evaluate the renal function in rats during GENTA treatment and after its suspension as well as its relationship with NO. Rats were treated with water (vehicle, CTL) or GENTA (100 mg/kg BW) intraperitonially during 10 days; both n=24. Twelve animals of each group were sacrificed after blood and 24 h urine were collected, and their kidneys were removed for histology. In another rats this procedure underwent after 20 or 30 days of GENTA suspension. GENTA treated group developed a marked decrease in renal function, characterized by an increased serum urea and decreased creatinine clearance; NO was increased in the serum and decreased in the urine; all P < 0.01 vs CTL. Acute tubular necrosis was confirmed in GENTA treated group. After GENTA suspension we observed a normalization of urea, creatinine clearance and serum and urinary NO; the histological lesions were also attenuated. We suggest that NO could play a role in GENTA induced nephrotoxicity and recovery. The understanding of this physiopathology could be an useful tool to prevent or blunt the nephrotoxicity progression, mainly when risk factors are present.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.niox.2010.12.001 | DOI Listing |
Pediatr Nephrol
September 2025
Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
Background: Kidney involvement in pediatric sarcoidosis is rare and often underrecognized, leading to diagnostic delays and treatment challenges. We report six patients with renal sarcoidosis to highlight their diverse presentations and outcomes and challenges in management.
Methods: Medical records of patients diagnosed with renal sarcoidosis during 2020-24 were reviewed.
J Nucl Med Technol
September 2025
Medical Physics Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
The glomerular filtration rate (GFR) is a key measure of renal function, typically estimated using creatinine-based equations. More precise clearance measurements are obtained with radiotracers, such as [Tc]Tc-diethylenetriaminepentaacetic acid (DTPA), and blood samples over several hours. However, standard plasma clearance methods require labor-intensive plasma preparation, limiting efficiency in clinical practice.
View Article and Find Full Text PDFHum Pathol
September 2025
Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address:
Renal cell carcinoma (RCC) is a heterogeneous kidney malignancy driven by complex genetic, molecular, and metabolic alterations. Emerging evidence implicates centrosome dysfunction and autophagy dysregulation in RCC initiation, progression, and resistance to therapy. The centrosome plays a critical role in mitotic fidelity, and its dysfunction often leads to chromosomal and genomic instability.
View Article and Find Full Text PDFClin Chim Acta
September 2025
Department of Physiology, University of Louisville, Louisville 40202 KY, USA. Electronic address:
Diabetic nephropathy (DN) is a major cause of end-stage renal disease, with podocyte injury representing an early pathogenic event. Conventional biomarkers such as albuminuria and eGFR identify renal damage only at advanced stages, limiting opportunities for timely intervention. Wilms' Tumor 1 (WT1), a podocyte-specific transcription factor, has emerged as a sensitive marker of early glomerular stress.
View Article and Find Full Text PDFHematol Transfus Cell Ther
September 2025
Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON, Canada; Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Th
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune disorder characterized by excessive inflammation and multiorgan involvement. Rarely, HLH can manifest with signs and symptoms isolated to the central nervous system (CNS). This case report highlights the unique clinical course of CNS-isolated HLH in a 19-year-old female who, despite a nine-year delay in diagnosis, achieved disease remission following a hematopoietic stem cell transplant (HSCT).
View Article and Find Full Text PDF